POST Online Media Lite Edition


Nile Therapeutics appoints Arie S. Belldegrun to board of directors

Staff writer |
San Francisco, Ca., USA - September 29, 2009, San Francisco, Ca., USA - Nile Therapeutics announced the appointment of Arie S. Belldegrun to its board of directors.

Article continues below

Dr. Belldegrun is Professor and Chief of Urologic Oncology, and holds the Carol and Roy Doumani Chair in Urologic Oncology, at the David Geffen School of Medicine at the University of California, Los Angeles. He is also the Chairman and a Partner at Two River Group Holdings, LLC, a New York-based venture capital firm. He was also the Vice-Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology, Inc., an oncology-focused biotechnology company. In July 2009, Johnson & Johnson acquired Cougar in a transaction valued at approximately $1 billion.


What to read next

US HIFU appoints Arie Belldegrun to board of directors
Hana Biosciences appoints Howard Furst to the board
Nile Therapeutics promotes Darlene Horton to CEO and director